Screener / SEC EDGAR /CIK 0001585364 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

PERRIGO Co plc PRGO

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of PRGO's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Aug 17, 2023
Questions asked 4 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 4 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 2 of 2 closing letter

Half the closed reviews took 49 days or less from the first letter to the closing letter.

Form 10-K for the Year Ended December 31, 2022

2023-08-17 to 2023-09-20 · 1 question · 1 letter from the SEC, 2 from the company
Review closed 2023-09-20
Non-GAAP measures
After reviewing your response to the comment, we may have additional comments. Form 8-K dated August 8, 2023 · Reconciliation of Non-GAAP Measures, page 13
SEC asked
Your reconciliation of Non-GAAP measures includes several line items and subtotals from the Statement of Operations. Please address the following: • Tell us why you believe your presentation is consistent with C&DI 102.10(a) and 102.10(c). • Tell us the nature of the $10.0 million milestone payments received related to royalty rights adjustment and why you believe the adjustment is consistent with C&DI 100.01.
Rest of the question

• Tell us why the $10.0 million adjustment is added in the Interest and Other column but subtracted in the Income from Continuing Operations column.

PRGO answered
We believe our reconciliation of non-GAAP measures is consistent with the guidance in C&DI 102.10(a) and C&DI 102.10(c) because, as presented, it does not give undue prominence to non-GAAP financial measures.

The reconciliation tables are not intended to constitute non-GAAP income statements and are not labeled or presented as income statements.
Rest of the answer

The reconciliations are presented in the tables at the end of the press release and appear after disclosure of the Company’s full GAAP condensed consolidated statement of operations, which is clearly identified as such.

Each table in the reconciliations begins with the GAAP measure, which is in bold font, and ends with the adjusted measure in non-bolded font. The purpose and context of the reconciliations are carefully explained in the press release and Form 8-K, and the specific adjusted measures are clearly indicated. As presented, we believe there is little likelihood of an investor confusing the reconciliation tables with the Company’s GAAP financial statements.

The measures and reconciliations are presented in groupings that have been specifically requested from the

Company’s investors and analysts. The totality of the presentation is meant to supplement the required reconciliations to provide additional detail on our adjustments to enhance investor understanding and be responsive to the requests that the

Company receives from analysts and investors. In addition, the Company believes that by presenting the various reconciliations in the concise format that it has employed, it provides investors with all reconciliations in an integrated and clear presentation. As such, we believe this presentation is fully consistent with Staff guidance and SEC rules and regulations regarding the presentation of non-GAAP financial measures.

Tell us the nature of the $10.0 million milestone payments received related to royalty rights adjustment and why you believe the adjustment is consistent with C&DI 100.01.

Response: The milestone payment relates to an agreement in 2006 pursuant to which Elan Pharmaceuticals sold the rights to Prialt™ in Europe (prior to Elan’s acquisition by the Company in 2013). Prialt™ is a non-opioid and non-NSAID analgesic agent used for the management of severe and chronic pain. The agreement provided for three potential milestone payments to Elan upon the achievement of certain net sales thresholds. One such milestone payment of $10.0 million was received in the three months ended July 1, 2023.

The Company exited the business related to this agreement in 2017. Accordingly, we do not consider this amount to be normal or recurring within the meaning of

C&DI 100.01 or indicative of the Company’s ongoing operations. A previous milestone payment, which was reported in the fourth quarter of 2017, was similarly excluded from the Company’s adjusted net income in the relevant periods.

Moreover, while a single remaining milestone payment under such agreement is possible, the receipt of such payment is uncertain and unlikely to be met, if at all, for many years. As such, we believe the exclusion of this non-recurring gain from adjusted net income to be consistent with Staff guidance, as well as our policy to treat income and gains consistently with expenses and losses when making non-GAAP adjustments.

Tell us why the $10.0 million adjustment is added in the Interest and Other column but subtracted in the

Income from Continuing Operations column

Response: The Prialt™ milestone payment was recorded on the Company’s condensed consolidated statement of operations as Other (income) expense, net. In both this line item of the income statement and the corresponding column in Table I of the reconciliations, income is expressed as a negative number, as the net amount is subtracted from Operating Income in the calculation of Income from Continuing Operations. Accordingly, to exclude the milestone payment from adjusted net income, there was a negative adjustment to the Income from Continuing Operations column in Table I and a corresponding positive adjustment to the Interest and Other column. We believe showing this detail in our reconciliations is helpful to investors and enhances their ability to compare our performance over time.

Read in the reply
In its next report

First report after the company's reply of Aug 25, 2023: 10-Q filed Nov 7, 2023 ↗, against the 10-Q filed Aug 8, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: company letter, Sep 14, 2023, closing letter, 2023-09-20

Form 8-K

2016-10-03 to 2016-11-21 · 3 questions · 2 letters from the SEC, 2 from the company
Review closed 2016-11-21
Non-GAAP measuresIncome taxes
Exhibit 99.1: Press release issued August 10, 2016 · Non-GAAP Measures, page 8
SEC asked (1)
In your next earnings release, please provide a more substantive, and concise, discussion of how each of your non-GAAP measures is useful to investors. Please provide us with your proposed changes in your response letter for the measures you expect to include in your next earnings release.
PRGO answered
We respectfully acknowledge the Staff’s comment and will revise our disclosure included in future earnings releases to enhance the description of the reasons why management believes our non-GAAP financial measures provide useful information to investors. Set forth below is an example of how we propose to enhance our future disclosures.
Rest of the answer

In addressing the usefulness of the non-GAAP measures, we have grouped them in three categories - profit measures, profit margins and net sales - as we view the measures within each group as helpful for similar reasons when used by our management and investors in evaluating our business. We expect our future disclosures would be substantially in this proposed form, with appropriate changes depending on the particular non-GAAP information.

Perrigo Company plc

Registered in Ireland, Registered number 529592

Registered office Treasury Building, Lower Grand Canal St., Dublin 2, Ireland

+353 1 7094000

Directors Laurie Brlas (U.S.), Gary M. Cohen (U.S.), Ellen R. Hoffing (U.S.), Michael J. Jandernoa (U.S.), Gary K. Kunkle, Jr (U.S.), Herman Morris, Jr (U.S.), Donal O'Connor (Ireland), Shlomo Yanai (Israel)

Non-GAAP Measures

This press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different than the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of income, balance sheets or statements of cash flows of the company. Pursuant to the requirements the U.S. Securities and Exchange Commission, the Company has provided reconciliations for adjusted net sales, adjusted gross profit, adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted gross margin, and adjusted operating margin within this press release to the most directly comparable U.S. GAAP measures for these non-GAAP measures. These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies.

The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or obscure underlying business operational trends. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management’s view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.

Non-GAAP measures related to profit measurements, which include adjusted gross profit, adjusted operating income, adjusted net income, and adjusted diluted earnings per share are useful to investors as they provide them with supplemental information to enhance their understanding of the Company’s underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company’s period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company’s peer business group and assisting them in comparing the Company’s overall performance to that of its competitors. The Company discloses adjusted net sales, which excludes operating results attributable to held-for-sale businesses, in order to provide information about sales of the Company’s continuing business. In addition, the Company discloses net sales growth and adjusted net sales growth on a constant currency basis to provide information about sales of the Company’s continuing business excluding the exogenous impact of foreign exchange. The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past, present and future underlying operating results, and also facilitate comparison of the Company’s operating performance to the operating performance of its competitors.

Directors Laurie Brlas (U.S.), Gary M. Cohen (U.S.), Ellen R. Hoffing (U.S.), Michael J. Jandernoa (U.S.), Gary K. Kunkle, Jr (U.S.), Herman Morris, Jr (U.S.), Donal O'Connor (Ireland), Shlomo Yanai (Israel)

Read in the reply
Table I: Reconciliation of Non-GAAP Measures · Selected Consolidated Information
SEC asked (2)
Please explain to us in detail how you calculated the income tax effects of your non- GAAP adjustments. See Question 102.11 of the updated Non-GAAP Compliance and Disclosure Interpretations issued on May 17, 2016.
PRGO answered
The following information and schedules provide detailed reconciliation of GAAP tax expense (benefit) reported in our Condensed Consolidated Statements of Operations to non-GAAP adjusted tax expense (benefit) for the three-months ended July 2, 2016 and June 27, 2015 included in our earnings release furnished on Form 8-K on August 10, 2016.

Income Tax Effect

($, millions) Three months ended,

June 27,

2015

July 2,

2016

GAAP income tax expense (benefit) per Statement of Operations

$

101.0

(42.7

)

Tax effect of non-GAAP adjustments in Table I (See Item 1 below)

44.5

(Figure
Rest of the answer

A)

40.1

(Figure B)

Annualized consolidated effective tax rate under ASC740 for interim reporting (See Item 2 below)

(33.3

(2a)

56.2

(2b)

Sub-Total Per Table I of August 10, 2016 Form 8-K

11.2

96.3

Valuation allowance adjustment related to acquisition (See Item 3 below)

(46.6

—

Total non-GAAP income tax expense

65.6

53.6

Non-GAAP pre-tax income

386.0

331.1

Non-GAAP effective tax rate

17.0

%

16.2

Tax expense (benefit) for non-GAAP net income is calculated in the following manner:

1)

The income tax expense (benefit) on non-GAAP pretax income adjustments is determined using the applicable tax rates for the jurisdictions that were utilized in calculating the original GAAP tax expense (benefit) on those same non-GAAP pretax adjustments and includes both current and deferred income tax expense (benefit). See Figure A and Figure B below for a detailed reconciliation of each non-GAAP pretax adjustment.

2)

The GAAP income tax expense (benefit) interim period tax accounting required under ASC 740, Income Taxes (“ASC740”) is adjusted for the non-GAAP pretax income adjustments and the respective income tax expense (benefit) outlined above. For the annual accounting fiscal year, this adjustment has no effect and only impacts interim period tax accounting.

Consistent with the requirements of ASC740, each quarter we calculate an estimated annual consolidated effective tax rate for non-GAAP pretax income. This estimate is based on the GAAP pretax income and tax expense (benefit) and non-GAAP pretax income adjustments at the applicable rates in the taxing jurisdiction for each respective adjustment. Under this method, income tax expense (benefit) for an interim year-to-date period is recorded based on the estimated annual effective tax rate applied to year-to-date pretax income, which results in an annualized impact to the quarterly income tax expense (benefit).

Calculation overview for each respective period presented:

a)

The three-month period ended June 27, 2015 was the fourth quarter of fiscal 2015. Based on the annual effective tax rate method, the cumulative adjustment for the difference in GAAP to non-GAAP taxes for ASC740 interim accounting through the first three quarters of fiscal 2015 was $33.3M. Therefore, the

Directors Laurie Brlas (U.S.), Gary M. Cohen (U.S.), Ellen R. Hoffing (U.S.), Michael J. Jandernoa (U.S.), Gary K. Kunkle, Jr (U.S.), Herman Morris, Jr (U.S.), Donal O'Connor (Ireland), Shlomo Yanai (Israel)

($33.3M) adjustment in the three-month period ended June 27, 2015 resulted in no difference (adjustment) between GAAP and non-GAAP interim tax accounting for the fiscal year.

b)

We changed our fiscal reporting year to align to the calendar year effective January 1, 2016. The three-month period ended July 2, 2016 was the second quarter of the Company's fiscal year. As disclosed in Note 13 - Income Taxes of our Form 10-Q filed August 10, 2016:

Income taxes recorded through July 2, 2016 were estimated using the discrete method. Due to sensitivity to small changes to forecasted annual pre-tax earnings, which created results with significant variations in the customary relationship between income tax expense and pre-tax income for the interim periods, we determined that using the discrete method is more appropriate than using the annual effective tax rate method.

In the first quarter of calendar 2016, we utilized the annual effective tax rate method. For the reasons cited in the footnote, in the second quarter ended July 2, 2016, the accounting election outlined above was adopted. Therefore, the $56.2M recorded in the second quarter ended July 2, 2016 for the GAAP to non-GAAP interim tax accounting was a reversal of the amount recorded in the first quarter. Accordingly, the cumulative effect of the difference between GAAP and non-GAAP interim tax accounting was zero for the six-month period ended July 2, 2016. Further, given our current expectation that the discrete method of interim tax accounting will remain in effect for calendar 2016, we do not expect any quarterly GAAP to non-GAAP interim tax accounting adjustment for the remainder of the year.

3)

In the three-month period ended June 27, 2015, we realized in the Statement of Operations GAAP tax expense a discrete tax item for an increase in the valuation allowance on a deferred asset impacted by the acquisition of Omega Pharma in this quarter. The $46.6M non-GAAP adjustment to tax expense adjusts for this unusual item.

Figure A: Reconciliation for the three months ended June 27, 2015 tax effect of non-GAAP pretax income adjustments itemized in Table 1 of August 10, 2016 Form 8-K

June 27, 2015

($, millions)

Amortization of intangible expense

Inventory fair value

R&D arrangement

Impairment charges

Restructuring charges

Derivative losses

Acquisition related integration charges

Mylan defense legal and consulting fees

Loss on early debt extinguish-ment

Total

Pretax income

$142.6

$15.6

$18.0

$9.0

$0.3

$5.5

$19.7

$13.4

$0.9

$225.0

Statutory tax effects(1)

(30.2)

(4.8)

(2.3)

(2.2)

(0.1)

(4.9)

(44.5)

Net income

$112.4

$10.8

$15.7

$6.8

$0.2

$14.8

$180.5

(1)

Tax effects of pretax non-GAAP adjustments are calculated based upon the specific rate of the applicable jurisdiction of the pretax item. Certain items in the pre-tax GAAP tax rate are non-deductible, therefore the impact on the non-GAAP tax rate is zero.

Figure B: Reconciliation for the three months ended July 2, 2016 tax effect of non-GAAP pretax income adjustments itemized in Table 1 of August 10, 2016 Form 8-K

July 2, 2016

Investment impairments

Held-for-sale businesses

Goodwill and impairment charges

$163.5

$24.1

$5.8

$2.1

$2.0

$(19.8)

$177.7

(34.1)

(1.6)

(0.5)

(0.3)

(3.6)

(40.1)

$129.4

$4.2

$1.6

$1.7

$(23.4)

$137.6

Directors Laurie Brlas (U.S.), Gary M. Cohen (U.S.), Ellen R. Hoffing (U.S.), Michael J. Jandernoa (U.S.), Gary K. Kunkle, Jr (U.S.), Herman Morris, Jr (U.S.), Donal O'Connor (Ireland), Shlomo Yanai (Israel)

Tax effects of pretax non-GAAP adjustments are calculated based upon the specific rate of the applicable jurisdiction of the pretax item. Certain items in the pre-tax GAAP tax rate are non-deductible, therefore the impact on the non-GAAP tax rate is zero.

In light of the Staff's comment, in future earnings releases we will enhance our disclosure related to income tax effects on our non-GAAP financial measures, consistent with the updated Compliance and Disclosure Interpretations issued on May 17, 2016. Set forth below is an example of a footnote we plan to include in our non-GAAP reconciliations to clarify the income tax expense (benefit) line item:

•

Tax effects of pretax non-GAAP adjustments are calculated based upon the specific rate of the applicable jurisdiction of the pretax item.

In addition, to the extent a non-GAAP adjustment is realized in a quarterly reporting period associated with interim tax accounting, we will include the following footnote:

The amount includes the calculated effect on non-GAAP income taxes related to the interim tax accounting requirements within ASC 740, Income Taxes.

If you would like additional information or desire to discuss our responses to your comments, please contact me directly at (269) 673-9308 or [email protected].

Read in the reply
Table I: Reconciliation of Non-GAAP Measures · Selected Consolidated Information
SEC asked
We acknowledge your response to prior comment 2. Please represent to us that in future earnings releases you will disclose the underlying cause for any material discrete income tax adjustments reflected in your non-GAAP earnings, including any specific adjustments recorded related to the interim tax accounting requirements within ASC 740.
PRGO answered
The Company represents that in its future earnings releases it will disclose the underlying cause for any material discrete income tax adjustments reflected in the Company’s non-GAAP earnings, including any specific adjustments recorded related to the interim tax accounting requirements within ASC 740.

If you would like additional information or desire to discuss our response to your comment, please contact me directly at (269) 673-9308 or [email protected].
Read in the reply

Also in this review: closing letter, 2016-11-21

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2016-10-03. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRGO/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.